# An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).

> **NCT06335979** · PHASE1 · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 54 (estimated)

## Conditions studied

- Systemic Lupus Erythematosus, SLE

## Interventions

- **DRUG:** PIT565

## Key facts

- **NCT ID:** NCT06335979
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2027-07-09
- **Final completion:** 2027-07-09
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06335979

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06335979, "An Ascending Dose Study of PIT565 in Participants With Systemic Lupus Erythematosus (SLE).". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06335979. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*